Pregled bibliografske jedinice broj: 679836
High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer
High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer // Medical oncology, 29 (2012), 3; 1586-1591 doi:10.1007/s12032-011-0120-9 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 679836 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
High expression of MAGE-A10 cancer-testis antigen in triple-negative breast cancer
Autori
Badovinac Črnjević, Tanja ; Spagnoli, Giulio ; Juretić, Antonio ; Jakić-Razumović, Jasminka ; Podolski, Paula ; Šarić, Nera
Izvornik
Medical oncology (1357-0560) 29
(2012), 3;
1586-1591
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
breast cancer; MAGE-A10; NY-ESO-1; cancer-testis antigens
(breast cancer; MAGE-A10; NY-ESO-1; cancer testis antigens)
Sažetak
Recent studies indicate that ER/PR/HER- 2-negative (triple-negative, TN) breast cancers may be "CTA-rich" tumors, suggesting the possibility of CTA based cancer vaccines as a treatment option for patients bearing these tumors. MAGE-A10 together with NY-ESO-1 is probably the most immunogenic CTA, representing a potentially highly attractive target of active specific immunotherapies. Paraffin-embedded tumor sections were collected retrospectively from 165 breast cancer patients diagnosed between 2002 and 2003. Immunohistochemical staining for MAGE-A10 and NY-ESO-1 was performed. The expression of MAGE-A10 and NY-ESO-1 was correlated with other clinicopathological variables. MAGE-A10 expression (score C 2?) was detected in 105/164 (64%), and NY-ESO-1 expression (score C 2?) was observed in 14/164 (8.5%) patients. No correlation between MAGE-A10 and NY-ESO-1 expression and tumor size, tumor grade, Ki-67 and lymph nodes status was detectable. MAGE-A10 expression was significantly associated with ER-negative (P = 0.002), PR-negative (P = 0.002) and HER-2-negative (P = 0.044) tumors.We clearly showed that MAGE-A10 is frequently expressed in the group of TN patients, where the majority (85.7%) of tumors express this CTA. Because of limited therapeutic options for the triple-negative breast cancer, the frequent expression of MAGE-A10 CTA in these cancers may offer the opportunity for a much needed additional treatment for this group of patients.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
214-0000000-3601 - Učinak zračenja u bolesnika s rakom prostate na Tregs-limfocite (Juretić, Antonio, MZOS ) ( CroRIS)
Ustanove:
Klinički bolnički centar Zagreb
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
